Barclays lowered the firm’s price target on Fate Therapeutics (FATE) to $2 from $10 and keeps an Overweight rating on the shares following the Q1 report. The firm has “derisked” Fate’s model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE: